Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12% Novo Nordisk vs Eli Lilly: Who's Winning the Obesity Drug Race? No change' for CagriSema as Novo ditches single chamber device Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Larvol Delta